Imprimis Pharmaceuticals Inc (IMMY.OQ)
20 Apr 2018
BRIEF-Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation
* IMPRIMIS PHARMACEUTICALS ISSUED COMPOSITION PATENT FOR NON-OPIOID CONSCIOUS SEDATION FORMULATION
* IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS
* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:
BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility
* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:
Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.
Allergan PLC can proceed with a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug, Restasis, a federal judge has ruled.
* Imprimis Pharmaceuticals announces third quarter 2017 results